Relapsed Diffuse Large B-Cell Lymphoma research hub
4 indexed studies · 2 currently recruiting
- active not recruitingPHASE3
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug combination for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to previous treatment. It compares the new drug with standard treatment to see if it works better.
United States · Argentina · Belgium - recruitingPHASE2
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at new drug combinations for a type of lymphoma called Diffuse Large B-cell Lymphoma (DLBCL). It's for people whose DLBCL has come back or hasn't responded to previous treatments. Researchers are testing two different drug combinations to see how safe and effective they are.
United States · Australia · Canada - recruitingPHASE2
DALY II USA/ MB-CART2019.1 for DLBCL
This study is testing a new cell therapy called zamtocabtagene autoleucel for different types of lymphoma, including Diffuse Large B-cell Lymphoma (DLBCL), when other treatments haven't worked. It looks at how well it works and if it's safe.
United States · Canada - active not recruitingPHASE3
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
This study compares two treatments for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded well to initial treatment. One treatment is a standard chemotherapy, and the other adds a new drug, polatuzumab vedotin, to that standard treatment.
Austria · Germany · Spain